How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

33,563 results for

Colorectal Cancer Screening

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. The clinical application of tumor markers in the screening of malignancies and interstitial lung disease of dermatomyositis/polymyositis patients: A retrospective study Full Text available with Trip Pro

detected: breast ductal carcinoma (n = 4), bladder transitional cell carcinoma (n = 2), lung adenocarcinoma (n = 2), cervical intraepithelial neoplasia 3 and papillary squamous cell carcinoma (n = 2), colorectal (colon and rectal adenocarcinoma) (n = 2), uterine adenocarcinoma (n = 1), nasopharyngeal carcinoma (n = 1) and hematological malignancy (myelodysplastic with excess blast cells) (n = 1). Among the patients with malignancies, 13 (86.7%) had dermatomyositis, 2 (13.3%) polymyositis and 3 (20 (...) The clinical application of tumor markers in the screening of malignancies and interstitial lung disease of dermatomyositis/polymyositis patients: A retrospective study To examine the clinical utility of tumor markers in dermatomyositis/polymyositis patients in Taiwan.Data were collected retrospectively from the database of Taichung Veterans General Hospital in Taiwan from 1998 to 2014. Patients who fulfilled Bohan and Peter criteria of dermatomyositis/polymyositis were recruited. Serum level

2018 SAGE open medicine

2. AIM Clinical Appropriateness Guidelines for Molecular Testing of Solid and Hematologic Tumors and Malignancies

Use Criteria 3 National Comprehensive Cancer Network® (NCCN®) Criteria* 4 Polycythemia Vera 5 Essential Thrombocythemia or Thrombocytosis 5 Primary Myelofibrosis 5 Breast Cancer 6 Cancer of Unknown Primary/Occult Neoplasm 7 Prostate Cancer 7 Screening 7 Confirmed Malignancy 7 Thyroid Cancer 7 Confirmed or Highly-Suspected Thyroid Cancer 7 Cytologically Indeterminate Thyroid Nodule 7 Colorectal Cancer Screening 8 CPT Codes 8 Background 12 Myeloproliferative Disorders 12 Polycythemia Vera 12 (...) Essential Thrombocythemia or Thrombocytosis 13 Primary Myelofibrosis 13 Solid Tumor Testing 13 Breast Cancer 13 Lung Cancer 15 Cell-Free Tumor Testing 16 Cancer of Unknown Primary/Occult Neoplasm 17 Prostate Cancer 17 Thyroid Cancer 18 Cancer Screening 18 Indeterminate Thyroid Nodules 18 Colorectal Cancer Screening 20 Professional Society Guidelines 21 Selected References 23 Revision History 26 PROPRIETARY Guidelines developed by, and used with permission from, Informed Medical Decisions, Inc. © 2019

2019 AIM Specialty Health

3. Nine primary malignant neoplasms-involving the esophagus, stomach, colon, rectum, prostate, and external ear canal-without microsatellite instability: a case report. Full Text available with Trip Pro

is extremely rare, the present case of nine primary malignancies with no associated microsatellite instability and no apparent predisposing hereditary conditions, is extraordinary. Our case study shows that it is possible for up to nine sporadic neoplasms to occur, and efficient disease management requires diligent screening and early detection. (...) Nine primary malignant neoplasms-involving the esophagus, stomach, colon, rectum, prostate, and external ear canal-without microsatellite instability: a case report. Although cases of multiple primary malignant neoplasms are increasing, reports of more than three or four primary metachronous malignant neoplasms are extremely rare. Moreover, very few publications have provided a genetic mutational analysis or have evaluated risk factors associated with such neoplasms. We present an extremely

2018 BMC Cancer

5. Management of Female Malignant Ovarian Germ Cell Tumours

treatment Women who have residual masses at completion of chemotherapy should be offered resection even if the tumour markers are normal. 41 This is to exclude residual disease or any residual mature teratoma which can progress as mature teratoma growing syndrome in up to 30% of cases, and more rarely, over time, undergo malignant transformation into an incurable tumour type, such as squamous carcinoma. Early recognition of this syndrome is essential as it offers hope for curative resection and avoids (...) for female malignant germ cell tumors. Obstet Gynecol 2006;107: 1075–85. 6. Arora RS, Alston RD, Eden TO, Geraci M, Birch JM. Comparative incidence patterns and trends of gonadal and extragonadal germ cell tumors in England, 1979 to 2003. Cancer 2012;118:4290–7. 7. Talerman A. Germ cell tumours of the ovary. In: Kurman RJ, editor. Blaustein’s Pathology of the Female Genital Tract. New York: Springer Verlag; 1994. p. 849. 8. Tewari K, Cappuccini F , Disaia PJ, Berman ML, Manetta A, Kohler MF . Malignant

2016 Royal College of Obstetricians and Gynaecologists

6. AIM Clinical Appropriateness Guidelines for Molecular Testing of Solid and Hematologic Tumors and Malignancies

Tumor Testing 10 Breast Cancer 10 Lung Cancer 12 Cell-Free Tumor Testing 13 Cancer of Unknown Primary/Occult Neoplasm 14 Prostate Cancer 14 Thyroid Cancer 15 Cancer Screening 15 Indeterminate Thyroid Nodules 15 Colorectal Cancer Screening 16 Professional Society Guidelines 18 Selected References 19 Revision History 20 PROPRIETARY Guidelines developed by, and used with permission from, Informed Medical Decisions, Inc. © 2017 Informed Medical Decisions, Inc. All Rights Reserved. 3 Scope This document (...) • Prostate Cancer Early Detection • Soft Tissue Sarcoma • Lung Cancer See more specific criteria below for: • Myeloproliferative neoplasms • Breast cancer • Cell-Free Tumor Testing • Cancer of Unknown Primary/Occult Neoplasm • Prostate Cancer (confirmed, not screening) • Thyroid Cancer and Indeterminate Thyroid Nodules • Colorectal Cancer Screening Polycythemia Vera JAK2 mutation testing is medically necessary for the diagnosis of polycythemia vera when both of the following conditions are met: • Genetic

2017 AIM Specialty Health

7. Role of gastrointestinal endoscopy in the screening of digestive tract cancers in Europ

leadtounderuseorpoorresourcingofhealthfacilities involved inprovidingscreeningservices, with consequent failuretofully realizethe potential benefits to patients. Methods In 2017, the European Society of Gastrointestinal Endoscopy (ESGE) Governing Board established a task force (Public Affairs Working Group led by A.S.) to produce a Position Statement concerning the value of endoscopy for screening purposes in GI cancers. The most prevalent digestive cancers (esophageal squamous cellcarcinoma,esophagealadenocarcinoma,gastric carcinoma (...) relative with BEor esophageal adenocarcinoma [EAC]). – For pancreatic cancer screening, endoscopic ultra- sound may be used in selected high-risk patients such as those with a strong family history and/or genetic suscep- tibility. ABBREVIATIONS BE Barrett’sesophagus CT computed tomography EAC esophageal adenocarcinoma ESGE European Societyof Gastrointestinal Endoscopy EUS endoscopic ultrasound FIT fecal immunochemical testing FOBT fecal occult blood test GERD gastroesophageal reflux disease GI

2020 European Society of Gastrointestinal Endoscopy

8. Risk of solid subsequent malignant neoplasms after childhood Hodgkin lymphoma-identification of high-risk populations to guide surveillance: A report from the Late Effects Study Group. Full Text available with Trip Pro

Risk of solid subsequent malignant neoplasms after childhood Hodgkin lymphoma-identification of high-risk populations to guide surveillance: A report from the Late Effects Study Group. Survivors of Hodgkin lymphoma (HL) in childhood have an increased risk of subsequent malignant neoplasms (SMNs). Herein, the authors extended the follow-up of a previously reported Late Effects Study Group cohort and identified patients at highest risk for SMNs to create evidence for risk-based screening (...) to be at a 14-fold increased risk of developing an sSMN (95% confidence interval, 12.0-fold to 16.3-fold). The cumulative incidence of any sSMN was 26.4% at 40 years after a diagnosis of HL. Risk factors for breast cancer among females were an HL diagnosis between ages 10 years and 16 years and receipt of chest radiotherapy. Males treated with chest radiotherapy at age <10 years were found to be at highest risk of developing lung cancer. Survivors of HL who were treated with abdominal/pelvic radiotherapy

2018 Cancer

9. Oral water soluble contrast for malignant bowel obstruction. Full Text available with Trip Pro

Oral water soluble contrast for malignant bowel obstruction. Malignant bowel obstruction (MBO) is a common problem in patients with intra-abdominal cancer. Oral water soluble contrast (OWSC) has been shown to be useful in the management of adhesive small bowel obstruction in identifying patients who will recover with conservative management alone and also in reducing the length of hospital stay. It is not clear whether the benefits of OWSC in adhesive small bowel obstruction are also seen (...) of patients screened, the number recruited and reasons for exclusion; this was not the focus of our review.Due to the low number of participants, the authors of the study decided not to report on our primary outcome of assessing the ability of OWSC to predict the likelihood of malignant small bowel obstruction resolving with conservative treatment alone (diagnostic effect). It also did not report on our primary outcome of rate of resolution of MBO in patients receiving OWSC compared with those

2018 Cochrane

10. The Clinical Landscape of Circulating Tumor DNA in Gastrointestinal Malignancies Full Text available with Trip Pro

in the screening, prognostication, molecular profiling, and monitoring of gastrointestinal malignancies. Although limitations continue to exist in the use of ctDNA, such as method standardization, the sensitivity, concordance with tumor tissue, and regulatory issues, this field offers promising benefits for cancer treatment. A deeper understanding of tumor biology via ctDNA analyses and ctDNA-guided clinical trials will lead to the increasing use of ctDNA in clinical practice in the near future (...) The Clinical Landscape of Circulating Tumor DNA in Gastrointestinal Malignancies Technologies for genomic analyses have revealed more details in cancer biology and have changed standard treatments for cancer, including the introduction of targeted gene-specific therapy. Currently, liquid biopsies are increasingly being utilized in clinical trials and research settings to analyze circulating tumor DNA (ctDNA) from peripheral blood. Several studies have shown the potential of ctDNA

2018 Frontiers in oncology

11. The Asia-Pacific Colorectal Screening Score Is Useful To Stratify Risk for Colorectal Advanced Neoplasms in Vietnamese Patients with Irritable Bowel Syndrome. (Abstract)

The Asia-Pacific Colorectal Screening Score Is Useful To Stratify Risk for Colorectal Advanced Neoplasms in Vietnamese Patients with Irritable Bowel Syndrome. The Asia-Pacific Colorectal Screening (APCS) score has been validated in several populations but not yet in patients with irritable bowel syndrome (IBS). The aim of this study was to assess the performance of APCS score in stratifying risk of colorectal advanced neoplasms (CAN) in Vietnamese IBS patients.Consecutive patients who fulfilled (...) and complete colonoscopy. The mean age was 48.8 ± 11.2 years and male : female ratio was 1.2:1. Twenty-eight patients (6.9%) were diagnosed with CAN: 19 (4.7%) advanced adenoma and 9 (2.2%) invasive colorectal cancer. Patients in the MR and HR tiers had 5.6-fold (95% confidence interval 1.2 to 24.7, P = 0.012) and 12.1-fold (95% confidence interval 2.6 to 56.2, P < 0.001) increased rates of CAN compared with those in the AR tier, respectively. Three out of 9 patients with invasive colorectal cancer had

2017 Journal of gastroenterology and hepatology

12. Bowel cancer screening: imaging use

screening: imaging use Information about imaging practice standards for bowel cancer screening of individuals unsuitable for a colonoscopy. Published 1 November 2012 Last updated 14 October 2019 — From: Documents Ref: PHE publications gateway number: GW-810 HTML Details This publication explains the use of whole colon imaging as an alternative to a colonoscopy as part of the NHS Bowel Cancer Screening Programme ( 14 October 2019 Added new guidelines on CTC imaging in NHS bowel cancer screening. 1 (...) Bowel cancer screening: imaging use Bowel cancer screening: imaging use - GOV.UK GOV.UK uses cookies which are essential for the site to work. We also use non-essential cookies to help us improve government digital services. Any data collected is anonymised. By continuing to use this site, you agree to our use of cookies. Accept cookies You’ve accepted all cookies. You can at any time. Hide Search Register by 26 November to vote in the General Election on 12 December. Guidance Bowel cancer

2019 Public Health England

13. Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies

Neoplasms Fibromatosis, Aggressive Cholangiocarcinoma Glomus Tumor Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Intestinal Neoplasms Gastrointestinal Neoplasms Digestive System Neoplasms Neoplasms by Site Digestive System Diseases Gastrointestinal Diseases Colonic Diseases Intestinal Diseases Rectal Diseases Lymphoma Lymphoproliferative Disorders Lymphatic Diseases Immunoproliferative Disorders Immune System Diseases Adenocarcinoma Hematologic Diseases Fibroma Neoplasms, Fibrous (...) on at least one line of systemic therapy and for whom no standard curative therapy exists. The following solid tumour indications are allowed to be enrolled into Part A of this study (dose escalation) based on known involvement of the NOTCH pathway activation in these indications: Breast cancer (triple negative breast cancer [TNBC], ER+/-, HER2+/-), gastrointestinal (GI) cancers (colorectal cancer [CRC], cholangiocellular carcinoma [CCC]), sarcomas (osteosarcoma, liposarcoma, rhabdomyosarcoma

2018 Clinical Trials

14. Kanglaite injection plus chemotherapy on the reduction of adverse effects and improvement of quality of life in patients with advanced malignant tumors of digestive tract: a meta-analysis of RCTs following the PRISMA guidelines

Kanglaite injection plus chemotherapy on the reduction of adverse effects and improvement of quality of life in patients with advanced malignant tumors of digestive tract: a meta-analysis of RCTs following the PRISMA guidelines Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate (...) : 1. Not an original full research paper (e.g. review, editorial) 2. Not an in vivo animal study 3. No metastases/ only primary tumor 4. No control group 5. Combination therapy or contamination 6. Not about analgesics used in the clinic Full text-screening: As above, with the addition of: 7. No relevant outcome measure reported ">Prioritise the exclusion criteria Example: Two reviewers will independently extract data from each article. We first try to extract numerical data from tables, text

2019 PROSPERO

15. Recommendations on fecal immunochemical testing to screen for colorectal neoplasia: a consensus statement by the US Multi-Society Task Force on colorectal cancer

Recommendations on fecal immunochemical testing to screen for colorectal neoplasia: a consensus statement by the US Multi-Society Task Force on colorectal cancer GIE SPECIAL ARTICLE Recommendations on fecal immunochemical testing to screen for colorectal neoplasia: a consensus statement by the US Multi-Society Task Force on colorectal cancer Douglas J. Robertson, 1,2, * Jeffrey K. Lee, 3, * C. Richard Boland, 4 Jason A. Dominitz, 5 Francis M. Giardiello, 6 David A. Johnson, 7 Tonya Kaltenbach (...) for the detection of cancer and advanced adenoma has been determined across a range of populations (Table 3). The PPV is a function of both the inherent sensitivity of the test and disease prevalence in the population studied. The PPV of FIT for cancer ranged from 2.9% to 7.8% and for advanced neoplasia ranged from 33.9% to 54%. A pos- itive FIT result signi?cantly increased the yield of colonos- copy for these important outcomes relative to a screening colonoscopy, in which cancer (0.5%–1%) and advanced

2017 American Society for Gastrointestinal Endoscopy

16. Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary Metastases

, histologically confirmed non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), esophageal carcinoma, thymic epithelial neoplasms, germ cell tumors, malignant pleural mesotheliomas or chest wall sarcomas, as well as patients with gastric, colorectal, pancreas or renal cancers, germ cell tumors and sarcomas metastatic to thorax are eligible. Histologic confirmation of disease in the Laboratory of Pathology, CCR, NCI, NIH. Germline ABCB4 (CC) and ABCB11 (GG or GC) genotypes determined (...) Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary Metastases Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary Metastases - Full Text View - ClinicalTrials.gov Hide glossary

2016 Clinical Trials

17. The predictive effect of primary tumour location in the treatment of metastatic colorectal cancer: a Canadian consensus statement

. Arai T, Kino I. Morphometrical and cell kinetic studies of normal human colorectal mucosa. Comparison between the proximal and the distal large intestine. Acta Pathol Jpn 1989;39:725–30. 7. Bara J, Nardelli J, Gadenne C, Prade M, Burtin P. Differences in the expression of mucus-associated antigens between proximal and distal human colon adenocarcinomas. Br J Cancer 1984;49:495–501. 8. Soong R, Powell B, Elsaleh H, et al. Prognostic significance of TP53 gene mutation in 995 cases of colorectal (...) . Dis Colon Rectum 2007;50:1783–99. 3. Bufill JA. Colorectal cancer: evidence for distinct genetic categories based on proximal or distal tumor location. Ann Intern Med 1990;113:779–88. 4. Rothberg PG, Spandorfer JM, Erisman MD, et al. Evidence that c-Myc expression defines two genetically distinct forms of colorectal adenocarcinoma. Br J Cancer 1985;52:629–32. 5. Delattre O, Olschwang S, Law DJ, et al. Multiple genetic alterations in distal and proximal colorectal cancer. Lancet 1989;2:353–6. 6

2018 CPG Infobase

18. Follow-up of Malignant or Aggressive Musculoskeletal Tumors

Follow-up of Malignant or Aggressive Musculoskeletal Tumors Date of origin: 1998 Last review date: 2015 ACR Appropriateness Criteria ® 1 Follow-up Musculoskeletal Tumors American College of Radiology ACR Appropriateness Criteria ® Clinical Condition: Follow-up of Malignant or Aggressive Musculoskeletal Tumors Variant 1: Lower-risk patient (low grade). Evaluation for metastatic disease to the lung from musculoskeletal primary. Baseline examination at time of diagnosis. Radiologic Procedure (...) Condition: Follow-up of Malignant or Aggressive Musculoskeletal Tumors Variant 3: Higher-risk patient (high grade). Evaluation for metastatic disease to the lung from musculoskeletal primary. Baseline examination at time of diagnosis. Radiologic Procedure Rating Comments RRL* CT chest without IV contrast 9 Despite some of the cost analysis studies, the panel believes early diagnosis of lung metastases is critical and that chest CT should be performed. If chest CT is done, chest x-ray is not necessary

2015 American College of Radiology

19. Head-to-Head Comparison of the Performance of 17 Risk Models for Predicting Presence of Advanced Neoplasms in Colorectal Cancer Screening. Full Text available with Trip Pro

Head-to-Head Comparison of the Performance of 17 Risk Models for Predicting Presence of Advanced Neoplasms in Colorectal Cancer Screening. Many risk scores have been proposed to predict presence of advanced colorectal neoplasms, but a comprehensive comparison conducted in the same population is sparse. The aim of this study was to evaluate and directly compare the diagnostic performance of published risk prediction models for advanced colorectal neoplasms.Data were drawn from 2 cohorts (...) of subjects undergoing screening colonoscopy in Germany, i.e., KolosSal (n = 16,195) and BliTz (n = 7,444). Absolute risks and relative risks were generated for the presence of at least 1 advanced neoplasm, taking the lowest risk group as the reference group. Performance of risk models was assessed by the area under the receiver operating characteristic curve (AUC) and compared by the net reclassification improvement.The 2 cohorts included 1,917 (11.8%) and 848 (11.4%) participants with advanced neoplasm

2019 American Journal of Gastroenterology

20. Trastuzumab (Kanjinti) Breast Neoplasms, Stomach Neoplasms

or early breast cancer whose tumours have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay (see sections 4.4 and 5.1). Assessment report EMA/CHMP/261937/2018 Page 7/71 Metastatic gastric cancer Kanjinti in combination with capecitabine or 5-fluorouracil and cisplatin is indicated for the treatment of adult patients with HER2 positive metastatic adenocarcinoma of the stomach or gastroesophageal junction who have not received prior anti-cancer (...) treatment for their metastatic disease. Kanjinti should only be used in patients with metastatic gastric cancer (MGC) whose tumours have HER2 overexpression as defined by IHC2+ and a confirmatory SISH or FISH result, or by an IHC 3+ result. Accurate and validated assay methods should be used (see sections 4.4 and 5.1). The legal basis for this application refers to: Article 10(4) of Directive 2001/83/EC – relating to applications for a biosimilar medicinal product. The application submitted is composed

2018 European Medicines Agency - EPARs

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>